127 related articles for article (PubMed ID: 28918915)
21. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
[No Abstract] [Full Text] [Related]
22. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
23. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
24. Enteritis with immune checkpoint inhibitor use.
Sanders D; Webber D; Chatur N
CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
[No Abstract] [Full Text] [Related]
25. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y
Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669
[No Abstract] [Full Text] [Related]
26. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis.
Paton DJW; Warburton L; Chung K; Meniawy TM; Kumarasinghe MP
Pathology; 2018 Jun; 50(4):466-469. PubMed ID: 29735170
[No Abstract] [Full Text] [Related]
28. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
[No Abstract] [Full Text] [Related]
29. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
30. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
van den Brom RR; Abdulahad WH; Rutgers A; Kroesen BJ; Roozendaal C; de Groot DJ; Schröder CP; Hospers GA; Brouwer E
Rheumatology (Oxford); 2016 Jun; 55(6):1143-5. PubMed ID: 27069016
[No Abstract] [Full Text] [Related]
31. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
Jørgensen LB; Yderstræde K
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
[TBL] [Abstract][Full Text] [Related]
32. Diarrhoea during checkpoint blockade, not always colitis.
Koldenhof JJ; Suijkerbuijk KPM
Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
[No Abstract] [Full Text] [Related]
33. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
[TBL] [Abstract][Full Text] [Related]
35. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
[No Abstract] [Full Text] [Related]
36. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
Ruff MW; Mauermann ML
Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
[TBL] [Abstract][Full Text] [Related]
37. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
38. Acute liver graft rejection after ipilimumab therapy.
Dueland S; Guren TK; Boberg KM; Reims HM; Grzyb K; Aamdal S; Julsrud L; Line PD
Ann Oncol; 2017 Oct; 28(10):2619-2620. PubMed ID: 28961840
[No Abstract] [Full Text] [Related]
39. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
40. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]